Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-α antagonists
| Autor: | Amer Alshekhlee, Kevian Basiri, Saef A. Ahmad, J. Douglas Miles, Bashar Katirji |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Male
Physiology Neural Conduction Pain Arthritis Chronic inflammatory demyelinating polyneuropathy Receptors Tumor Necrosis Factor Etanercept Arthritis Rheumatoid Cellular and Molecular Neuroscience Paraparesis Physiology (medical) medicine Humans Peripheral Nerves Muscle Skeletal Immunosuppression Therapy Muscle Weakness Tumor Necrosis Factor-alpha business.industry Electrodiagnosis Antibodies Monoclonal Immunoglobulins Intravenous Polyradiculoneuropathy Recovery of Function Middle Aged medicine.disease Infliximab Treatment Outcome Peripheral neuropathy Polyradiculoneuropathy Chronic Inflammatory Demyelinating Antirheumatic Agents Immunoglobulin G Rheumatoid arthritis Immunology Female Tumor necrosis factor alpha Neurology (clinical) business medicine.drug |
| Zdroj: | Muscle & Nerve. 41:723-727 |
| ISSN: | 1097-4598 0148-639X |
| DOI: | 10.1002/mus.21584 |
| Popis: | Biologic therapy with tumor necrosis factor (TNF)-alpha antagonists for rheumatoid arthritis has been well established. We describe two patients with rheumatoid arthritis who developed chronic inflammatory demyelinating polyneuropathy (CIDP) during their course of therapy with TNF-alpha antagonists. A 45-year-old woman and a 49-year-old man, both with a history of rheumatoid arthritis, were treated with etanercept and infliximab, respectively. Clinical signs of peripheral neuropathy developed 2 weeks and 12 months after the initiation of TNF-alpha antagonists. Electrodiagnostic studies at variable points during the disease course showed signs of acquired demyelination consistent with CIDP. Cerebrospinal fluid examination showed albuminocytologic dissociation (total protein concentration 118 mg/dl and 152 mg/dl, respectively). Both patients failed to improve after discontinuation of the offending agent, and they responded poorly to corticosteroids. However, there was clinical and electrophysiologic recovery after initiation of intravenous immunoglobulin (IVIg) therapy. CIDP may occur early or late during the treatment course with TNF-alpha antagonists. IVIg may reverse and stabilize the inflammatory process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text